Prostate cancer detection rate of transrectal ultrasonography, digital rectal examination, and prostate-specific antigen: Results of a five-year study of 6- versus 12-core transperineal prostate biopsy;La diagnosi del tumore prostatico con ecografia transrettale, esplorazione rettale e antigene prostatico specifico: Risultati di 5 anni di studio comparato fra biopsia prostatica transperineale a 6 e 12 prelievi 406

Minerva Urologica e Nefrologica

Volumn 59, Issue 4, 2007, Pages 395-406

  Bigliocchi, M ^a,b   Marini, M ^a   Nofroni, I ^a   Perugia, G ^a   Shahabadi, H ^a   Ciccariello, M ^a  

^a POLICLINICO UMBERTO I   (Italy)

^b NONE   (Italy)

Author keywords

Biopsy; Prostate; Prostatic neoplasms; Prostatitis; Ultrasonography

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

BIOPSY, NEEDLE; DIGITAL RECTAL EXAMINATION; ENDOSONOGRAPHY; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 37049005178     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ochiai A, Babaian RG. Update on prostate biopsy technique. Curr Opin Urol 2004;14:157-62.
2. Emiliozzi P, Scarpone P, DePaula F, Pizzo M, Federico G, Pansadoro A et al. The incidence of prostate cancer in men with prostate specific antigen greater than 4 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy. J Urol 2004;171:197-9.
3. Takenaka A, Hara R, Hyodo Y, Ishimura T, Sakai Y, Fujioka H et al. Transperineal extended biopsy improves the clinically significant prostate cancer detection rate: a comparative study of 6 and 12 biopsy cores. Int J Urol 2006;13:10-4.
4. Luciani LG, De Giorgi G, Valotto C, Zanin M, Bierti S, Zattoni F. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/ml and abnormal digital rectal examination findings. Urology 2006;67:555-8.
5. Kim JW, Lee HY, Hong SJ, Chung BH. Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core? A prospective randomized study in Korea. Yonsei Med J 2004;45:671-5.
6. Kojima M, Hayakawa T, Saito T, Mitsuya H, Hayase Y. Transperineal 12-core systematic biopsy in the detection of prostate cancer. Int J Urol 2001;8:301-7.
7. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 2000;164:388-92.
8. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000;163:152-7.
9. Ravery V, Goldblatt L, Royer B, Blanc E, Toublanc M, Boccon-Gibod L. Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 2000;164: 393-6.
10. Gann PH, Ma J, Catalona WJ, Stampfer MJ. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 2002;167:2427-34.
11. Pelzer AE, Volgger H, Bektic J, Berger AP, Rehder P, Bartsch G et al. The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA le-vels. BJU 2005;96:995-8.
12. Minardi D, Galosi AB, Recchioni A, Giammarco L, Polito M, Muzzonigro G. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients. Urol Int 2001;67:272-82.
13. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol 1968;49:347-57.
14. Difuccia B, Keith I, Teunissen B, Moon T. Diagnosis of prostatic inflammation: efficacy of needle biopsy versus tissue blocks. Urology 2005;65:445-8.
15. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999;84:976-81.
16. rd ed. Philadelphia: Lippincott Williams e Wilkins; 2002. p. 19-32.
17. Yaman O, Gogus C, Tulunay O, Tokatli Z, Ozden E. Increased prostate-specific antigen in subclinical prostatitis: the role of aggressiveness and extension of inflammation. Urol Int 2003;71:160-4.
18. Potts JM. Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol 2000;164:1550-3.
19. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 2000;37:404-12.
20. Sindhwani P, Wilson CM. Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005;6: 307-12.
21. Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 2002;167:1723-6.
22. Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001;165:757-60.
23. Yamamoto S, Kin U, Nakamura K, Hamano M, Nishikawa Y, Takenouchi T et al. Transperineal ultrasound-guided 12-core systematic biopsy of the prostate for patients with a prostate-specific antigen level of 2.5-20 ng/ml in Japan. Int J Clin Oncol 2005;10:117-21.
24. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006;175:820-34.